Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger CCCH-type containing 12A, most commonly known as Regnase-1 or MCPIP-1 (gene: ZC3H12A), is a CCCH-type zinc finger protein that functions as an endoribonuclease and plays a crucial role in the post-transcriptional regulation of inflammatory responses[1][2][5]. It degrades specific mRNAs (notably those encoding inflammatory cytokines such as IL-6 and IL-12b) by recognizing stem-loop structures in their 3’ untranslated regions, thereby preventing excessive or chronic inflammation[1]. The activity of Regnase-1 is tightly regulated by post-translational modifications, cytoplasmic-nuclear shuttling, and interaction with regulatory proteins such as 14-3-3 and βTRCP, which control its activity and stability[1]. Mice deficient in Zc3h12a exhibit heightened inflammatory responses and autoimmunity, underscoring its significance as a negative regulator of immune activation[1]. While ZC3H12A is clearly implicated in the control of inflammation and immune homeostasis and is an attractive therapeutic target, there are currently no approved drugs that directly target this protein[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger CCCH-type containing 12A (ZC3H12A).